OmniComm Systems, Inc. Appoints 18-Year Industry Veteran Dr. Yvonne Rollinger To Spearhead Global Clinical Electronic Data Capture Services

Latest Hire Brings The Total To 15 Additional Industry Experienced Executives Hired In Q2, 2007 To Support The Needs Of The Company's Rapidly Growing Customer Base

FT. LAUDERDALE, FL - August 16, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that it has strengthened its client services and support management team with the addition of Dr. Yvonne Rollinger. As Director of Clinical Operations based in OmniComm's Bonn, Germany facility, Dr. Rollinger will be responsible for leading the charge to deliver best-in-class clinical services and client support to OmniComm's rapidly growing base of EDC customers.

"OmniComm's number one goal is to provide our clients with the best possible EDC solutions for drug development with the right team of people to deliver the level of clinical services and support that our customers deserve," said Cornelis F. Wit, CEO of OmniComm. "Building our teams with the clinical depth of people like Dr. Rollinger is a direct reflection of our company's commitment to support the industry that we serve with an experienced leadership team. Dr. Rollinger's expertise is an invaluable asset to OmniComm and our customers."

Dr. Rollinger comes to OmniComm from DATATRAK International where she spent 7 years as Director Clinical Services Europe. In her most recent position, she served as Senior Consultant, leading multinational clinical trials as a key member of the company's technology transfer and EDC workflow consulting program for international clients. Prior to DATATRAK, she worked as a project coordinator for a US based CRO coordinating international clinical trials in Phases II and III in cooperation with the MIMC headquarters in Rockville, MD. Dr. Rollinger held previous positions as a CRA for a German based pharmaceutical and a German based CRO, conducting clinical trials in all clinical phases, writing scientific reports and publications and developing SOPs.

"Dr. Rollinger joins OmniComm at a very exciting juncture in the history of our company. We are growing at an expeditious rate and we have increased our support teams to meet that demand. Since the beginning of Q2, 2007, we have added 15 new hires that include Project Managers, Study Designers and Client Services and Support professionals that are all seasoned industry veterans. Their clinical development industry experience spans a total of 161 years. Industry experience is a crucial ingredient to delivering high quality EDC services and we are bringing the best and brightest talent on board at OmniComm for our customers, said Mr. Wit."

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. The company has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Back